By Exec Edge Editorial Staff Potbelly Corp. (Nasdaq: PBPB) said third quarter revenue increased by 2.7% to $120.8 million compared to $117.6 million a year earlier. Shop-level margins and same-store sales grew in the quarter, driven by increased customer...

By Thomas Green Portillo’s Inc. (Nasdaq: PTLO) said third quarter revenue rose 10.4% to $166.8 million as it added new restaurants. The Chicago-style, fast-casual chain’s operating income increased $4.5 million to $15.1 million this quarter and Restaurant-Level Adjusted EBITDA increased...

By Daniella Parra Eterna Therapeutics Inc. (Nasdaq: ERNA) said it appointed Dr. James Bristol, an experienced biopharmaceutical executive with a background in research and drug discovery, to its Board of Directors. Before his retirement from Pfizer in 2007, Dr. Bristol...

By Thomas Green First Watch Restaurant Group, Inc. (Nasdaq: FWRG) said third quarter revenue rose 17% to $219.2 million from a year earlier. After opening 13 new locations, the group now has over 500 restaurants, the company said in a...

By Daniella Parra Betterware de Mexico S.A.P.I. de C.V. (NASDAQ: BWMX) said Ebitda in the third quarter rose 10 percent from a year earlier. Ebitda was Ps. 328M with a 3.3pp margin expansion, while revenue showed stability for the fourth...

By Daniella Parra Avertix Medical presented new data regarding its Guardian System, which can detect heart attacks in real-time and alert high-risk patients, at the Transcatheter Cardiovascular Therapeutics (TCT) conference, the company said. Avertix said it showed a 150% increase...

Tim Fitzgerald, American Seafoods Chief Sustainability Officer By Exec Edge Editorial Staff Sustainability is ubiquitous in business. But consumers may not realize how much effort goes into making seafood sustainable, from fisheries management to ships to innovation. Exec Edge spoke...

By Daniella Parra Sparrow Pharmaceuticals said it initiated a Phase 2 ACSpire study for SPI-62, a potent HSD-1 inhibitor, targeting autonomous cortisol secretion (ACS). ACS results from excessive cortisol production due to benign adrenal tumors and can lead to severe...

By Daniella Parra Apollomics Inc. (Nasdaq: APLM) unveiled results from the KUNPENG clinical trial at ESMO 2023, showing vebreltinib’s potential as a treatment for cancers with MET alterations, they said. The Phase 2 trial by Apollomics’ partner, Avistone Biotechnology Ltd.,...

Tech Edge hosted several fireside chats with AvePoint (Nasdaq: AVPT), live at the #shifthappens Conference in Washington, D.C. The interviews were conducted by IPO Edge Editor-in-Chief John Jannarone  and  Editor-at-Large Jarrett Banks, discussing a range of topics including the use...